Abstract 2116P
Background
Body mass index (BMI) and waist circumference (WC) were used to evaluate nutritional status and obesity.We aimed to examine whether preoperative BMI or WC was associated with mortality after cancer surgery.
Methods
As a population-based cohort study, this study used data extracted from the National Health Insurance Service database of South Korea.We included 87,220 adult patients who underwent major cancer surgery with curative intent between January 1, 2016, and December 31, 2020.
Results
A total of 87,220 patients were included in the final analysis, and 1,374 (1.6%) died within 90 days after cancer surgery. In the multivariable logistic regression model, the BMI <18.5/kg/m2 and >35 kg/m2 groups showed 1.98-fold (odds ratio [OR]: 1.98, 95% confidence interval [CI]: 1.58, 2.49; P<0.001) and 2.62-fold (OR: 2.62, 95% CI: 1.26, 5.45; P<0.001) higher 90-day mortality after cancer surgery than did the BMI 18.5–24.9 kg/m2 group. The 25.0–29.9 kg/m2 (P=0.143) and 30.0–34.9 kg/m2 (P=0.109) BMI groups did not show significant differences compared to the BMI 18.5–24.9 kg/m2 group. Compared with the normal WC group, the high (P=0.052) and very high (P=0.236) WC groups also did not show significant differences in terms of 90-day mortality.
Table: 2116P
Subgroup analyses for 90-day mortality according to cancer surgery type
Surgery | OR (95% CI) | P-value |
Lung cancer | ||
BMI: <18.5 | 1.89 (1.08, 3.29) | 0.025 |
BMI: 25.0–29.9 | 0.82 (0.59, 1.14) | 0.235 |
BMI: 30.0–34.9 | 0.97 (0.37, 2.59) | 0.954 |
BMI: >35.0 | 5.91 (1.19, 29.312) | 0.030 |
Gastric cancer | ||
BMI: <18.5 | 2.47 (1.49, 4.10) | <0.001 |
BMI: 18.5–24.9 | 1 | |
BMI: 25.0–29.9 | 0.99 (0.70, 1.39) | 0.944 |
BMI: 30.0–34.9 | 0.32 (0.09, 1.11) | 0.072 |
BMI: >35.0 | 1.62 (0.20, 13.26) | 0.654 |
Colorectal cancer | ||
BMI: <18.5 | 2.36 (1.53, 3.65) | <0.001 |
BMI: 25.0–29.9 | 0.91 (0.68, 1.24) | 0.556 |
BMI: 30.0–34.9 | 1.01 (0.47, 2.19) | 0.979 |
BMI: >35.0 | 4.67 (1.23, 17.73) | 0.024 |
Liver cancer | ||
BMI: <18.5 | 2.22 (1.11, 4.43) | 0.024 |
BMI: 25.0–29.9 | 0.78 (0.52, 1.17) | 0.227 |
BMI: 30.0–34.9 | 0.62 (0.20, 1.94) | 0.409 |
BMI: >35.0 | 1.09 (0.12, 9.88) | 0.941 |
OR, Odds ratio; CI, confidence interval; BMI, body mass index; WC, waist circumference
Conclusions
Preoperative BMI <18.5 kg/m2 and >35 kg/m2 are associated with an elevated risk of 90-day mortality after major cancer surgery. However, preoperative WC was not significantly associated with 90-day mortality after cancer surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
N/A.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06